Roslyn C Malley
Overview
Explore the profile of Roslyn C Malley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
90
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wilkinson E, Raspin K, Malley R, Donovan S, Nott L, Holloway A, et al.
Cancer Med
. 2024 Aug;
13(16):e70122.
PMID: 39164966
Background: Current diagnostic tools are unable to distinguish low-grade indolent prostate cancer (PrCa) from that with a propensity to become metastatic and/or lethal. Recent evidence suggests that reprogramming of the...
2.
Raspin K, Marthick J, Donovan S, Blizzard L, Malley R, Jung C, et al.
Genes Chromosomes Cancer
. 2022 Dec;
62(5):247-255.
PMID: 36520140
Recurrent tumor copy number variations (CNVs) in prostate cancer (PrCa) have predominantly been discovered in sporadic tumor cohorts. Here, we examined familial prostate tumors for novel CNVs as prior studies...
3.
Raspin K, OMalley D, Marthick J, Donovan S, Malley R, Banks A, et al.
Prostate
. 2022 Jan;
82(5):540-550.
PMID: 34994974
There is strong interest in the characterisation of gene fusions and their use to enhance clinical practices in prostate cancer (PrCa). Significantly, ~50% of prostate tumours harbour a gene fusion....
4.
Marthick J, Raspin K, Foley G, Blackburn N, Banks A, Donovan S, et al.
Eur J Cancer
. 2021 Nov;
159:52-55.
PMID: 34736042
No abstract available.
5.
Raspin K, FitzGerald L, Marthick J, Field M, Malley R, Banks A, et al.
Int J Cancer
. 2021 Apr;
149(5):1089-1099.
PMID: 33821477
Prostate cancer (PrCa) is highly heritable, and although rare variants contribute significantly to PrCa risk, few have been identified to date. Herein, whole-genome sequencing was performed in a large PrCa...
6.
Wilkinson E, Woodworth A, Parker M, Phillips J, Malley R, Dickinson J, et al.
Exp Cell Res
. 2020 May;
392(2):112055.
PMID: 32376286
Examination of epigenetic changes at the ITGB4 gene promoter reveals altered methylation at different stages of prostate tumour progression and these changes may, in part, explain the complex patterns of...
7.
Choi-Lundberg D, Al-Aubaidy H, Burgess J, Clifford C, Cuellar W, Errey J, et al.
Med Teach
. 2019 Aug;
42(1):58-65.
PMID: 31437065
Various pressures exist for curricular change, including economic forces, burgeoning knowledge, broadening learning outcomes, and improving quality and outcomes of learning experiences. In an Australian 5-year undergraduate medical course, staff...
8.
FitzGerald L, Raspin K, Marthick J, Field M, Malley R, Thomson R, et al.
Sci Rep
. 2017 Dec;
7(1):17778.
PMID: 29259341
The HOXB13 G84E variant is associated with risk of prostate cancer (PCa), however the role this variant plays in PCa development is unknown. This study examined 751 cases, 450 relatives...
9.
Tovar C, Pye R, Kreiss A, Cheng Y, Brown G, Darby J, et al.
Sci Rep
. 2017 Mar;
7:43827.
PMID: 28276463
Devil facial tumour disease (DFTD) is a transmissible cancer devastating the Tasmanian devil (Sarcophilus harrisii) population. The cancer cell is the 'infectious' agent transmitted as an allograft by biting. Animals...
10.
Ambrose M, Malley R, Warren S, Beggs S, Swallow O, McEwan B, et al.
Front Microbiol
. 2016 Jun;
7:692.
PMID: 27242717
Pandoraea species are considered as emerging pathogens in people with cystic fibrosis (CF). The contribution of these organisms to disease progression in CF patients is not fully understood owing in...